Is the treatment beneficial, experimental, or futile?

Cambridge Quarterly of Healthcare Ethics

Volumn 5, Issue 2, 1996, Pages 248-256

  Schneiderman, Lawrence J ^a   Jecker, Nancy S ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADENOCARCINOMA; ADULT; ALTERNATIVE MEDICINE; ARTICLE; BIOMEDICAL AND BEHAVIORAL RESEARCH; BIOMEDICAL TECHNOLOGY ASSESSMENT; BONE MARROW TRANSPLANTATION; BREAST TUMOR; CASE REPORT; COST CONTROL; ECONOMICS; EXPERIMENTAL THERAPY; FEMALE; HEALTH CARE AND PUBLIC HEALTH; HUMAN; HUMAN EXPERIMENT; INTERPERSONAL COMMUNICATION; JURISPRUDENCE; LEGAL ASPECT; PATIENT RIGHT; PROFESSIONAL PATIENT RELATIONSHIP; RISK ASSESSMENT; TREATMENT OUTCOME; UNCERTAINTY; UNITED STATES;

BIOMEDICAL AND BEHAVIORAL RESEARCH; HEALTH CARE AND PUBLIC HEALTH; PROFESSIONAL PATIENT RELATIONSHIP;

ADENOCARCINOMA; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW TRANSPLANTATION; BREAST NEOPLASMS; COMPLEMENTARY THERAPIES; COST CONTROL; DISCLOSURE; FEMALE; HUMAN EXPERIMENTATION; HUMANS; JUDICIAL ROLE; MEDICAL FUTILITY; PATIENT RIGHTS; RISK ASSESSMENT; TECHNOLOGY, HIGH-COST; THERAPEUTIC HUMAN EXPERIMENTATION; THERAPIES, INVESTIGATIONAL; TREATMENT OUTCOME; UNCERTAINTY; UNITED STATES;

EID: 0030101635     PISSN: 09631801     EISSN: None     Source Type: Journal    
DOI: 10.1017/s0963180100007003     Document Type: Article

References (19)

1. Grimes DA. Technology follies: the uncritical acceptance of medical innovation. Journal of the American Medical Association 1993;269:3030-3.
2. Taylor v. Blue Cross/Blue Shield of Michigan. 205 Mich. App 644; 517 N.W. 2d 804; 1994 Mich. App. 291; 18 E.B.C. 1711.
3. Eddy DM. High-dose chemotherapy with autologous bone marrow transplantation for the treatment of metastatic breast cancer. Journal of Clinical Oncology 1992;10(4):657-70.
4. Meyer H. Breast study woes preview reform barriers. American Medical News 1993;March 8:1,8.
5. Schoenbaum SC. Towards fewer procedures and better outcomes. Journal of the American Medical Association 1993;269:794-6.
6. Cohen J. Somber news from the AIDS front. Science 1993;260:1712-3.
7. Schneiderman LJ, Jecker NS, Jonsen AR. Medical futility: its meaning and ethical implications. Annals of Internal Medicine 1990;1112:949-54.
8. Schneiderman LJ, Jecker, NS. Futility in practice. Archives of Internal Medicine 1993;153:437-41.
9. Schneiderman LJ, Faber-Langendoen K, Jecker NS. Beyond futility to an ethic of care. American Journal of Medicine 1994;96:110-4.
10. Schneiderman LJ, Jecker NS. Wrong Medicine: Doctors, Patients and Futile Treatment. Baltimore, Maryland: Johns Hopkins University Press, 1995.
11. Chalmers TC. Ethical aspects of clinical trails. American Journal of Ophthalmology 1975;79:753-8.
12. Altman LK. Drug mixture curbs HIV in lab, doctor's report, but urge caution. The New York Times 1993;Feb 18:A1 (col 1).
13. Altman LK. Fatal drug trial raises questions about "informed consent" New York Times 1993;Oct 5:col B7.
14. Jecker NS, Schneiderman LJ. Medical futility: the duty not to treat. Cambridge Quarterly of Healthcare Ethics 1993;2:151-9.
15. Faber-Langendoen K. Resuscitation of patients with metastatic cancer: is transient benefit still futile? Archives of Internal Medicine 1991;151:235-9.
16. Vitelli CE, Cooper K, Rogatko A, Brennan MF. Cardiopulmonary resuscitation and the patient with cancer. Journal of Clinical Oncology 1991;9(1):111-5.
17. Phelps CE. The methodologic foundations of studies of the appropriateness of medical care. New England Journal of Medicine 1993;329:1241-5.
18. The University Group Diabetes Program: a study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. Diabetes 1970;19(Suppl 2):747.
19. Wang PH, Lau J, Chalmers TC. Meta-analysis of effects of intensive blood-glucose control on late complications of type I diabetes. Lancet 1993;341:1306-9.